Latest Sanofi Stories
DALLAS, July 23, 2014 /PRNewswire/ -- Expiring biologic human insulin market drugs' patents are set to create new opportunities for biosimilar drugs, which is estimated
DUBLIN, July 18, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/3txjqf/global_type_1) has announced the addition of the "Global
Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine TARRYTOWN, N.Y. and PARIS, July 9, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
- Toujeo dossier already accepted by EMA - PARIS, July 8, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.
STOCKHOLM, July 3, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, is very pleased to announce that Mrs Ann-Tove Kongsnes,
ALBANY, N.Y., July 1, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris
- Triggered by ongoing and very successful multi-year collaboration TUBINGEN, Germany, July 1, 2014 /PRNewswire/ -- CureVac, a German clinical-stage biopharmaceutical company, today
MONTREAL, June 30, 2014 /CNW Telbec/ - For more than 75 youngsters with life-threatening allergies, participating in a soccer clinic hosted by the Montreal Impact and Allerject(TM) was a dream
ALBANY, N.Y., June 23, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in
PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study
- a study of the individuals in a group of people within a specific context and their relationships.
- In rhetoric, the description of any one's personal appearance.